Sitaxsentan in Proteinuric Chronic Kidney Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by University of Edinburgh.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Encysive Pharmaceuticals
Information provided by:
University of Edinburgh
ClinicalTrials.gov Identifier:
NCT00817037
First received: January 5, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
  Purpose

Patients with chronic kidney disease (CKD) have higher blood pressures than the general population. They also tend to have protein leaking into the urine (proteinuria). CKD, high blood pressure and proteinuria independently and together increase the risk of developing atherosclerosis (hardening) of the arteries that leads to diseases such as heart attack and stroke. Although there are a number of drugs available that lower blood pressure, these are not always fully effective. Furthermore, there are even fewer drugs that simultaneously lower blood pressure, reduce proteinuria, and slow down kidney damage in CKD.

Recent research has shown that drugs like sitaxsentan not only lower blood pressure but also reduce proteinuria and potentially slow down the progression of CKD [1,2]. Before sitaxsentan can become freely available to individuals with CKD it is important to look at the effects this drug could have on proteinuria and blood pressure.

  1. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
  2. Krum H, Viskoper RJ, Lacourciere Y et al. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med 1998;338:784-790.

Condition Intervention Phase
Chronic Kidney Disease
Proteinuria
Blood Pressure
Drug: Sitaxsentan
Drug: Nifedipine
Drug: Placebo tablet
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-Hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by University of Edinburgh:

Primary Outcome Measures:
  • The principal objective of this study is to evaluate whether sitaxsentan reduces proteinuria in people with chronic kidney disease. [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary objective of this study is to evaluate whether sitaxsentan reduces systemic blood pressure in people with chronic kidney disease. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Secondary objective is to determine whether sitaxsentan improves indices of arterial stiffness in people with chronic kidney disease [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Secondary objectives is to determine the safety of sitaxsentan in chronic kidney disease [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 27
Study Start Date: May 2007
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sitaxsentan

Once daily oral sitaxsentan 100mg given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Sitaxsentan
Sitaxsentan 100mg once daily oral dosing for 6 weeks
Other Name: Thelin
Placebo Comparator: Placebo

Once daily oral placebo tablet given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Placebo tablet
Placebo tablet once daily oral dosing for 6 weeks
Active Comparator: Nifedipine

Open labeled active comparator

Once daily oral nifedipine 30mg given over a period of 6 weeks.

24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment

Drug: Nifedipine
Nifedipine 30mg once daily oral dosing for 6 weeks
Other Name: Adalat LA

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Has Stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (using the Cockcroft and Gault equation for calculation of glomerular filtration rate) with proteinuria, including any of the following aetiologies: immunoglobulin A (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.
  2. Is between 18 and 70 years of age, inclusive.
  3. Has a body mass index (BMI) between 18 and 35 kg/m2, inclusive.
  4. Is willing and able to adhere to the protocol requirements.
  5. Provides written informed consent before any study procedure is performed.

Exclusion Criteria:

  1. Requires peritoneal dialysis or haemodialysis.
  2. Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.
  3. Has a serum albumin in the nephrotic range (< 30 g/L) during Screening.
  4. Has a sustained sitting systolic blood pressure (BP) > 160 mmHg or sustained sitting diastolic BP > 100 mmHg during Screening.
  5. Has postural hypotension during Screening, which is defined as a decrease in systolic BP ≥ 20 mmHg and/or a decrease in diastolic BP ≥ 10 mmHg, comparing sitting and standing measurements.
  6. Has a history and/or evidence of ischaemic heart disease.
  7. Has or had a malignancy, with the exception of adequately-treated basal cell or squamous cell carcinoma of the skin, that required significant medical intervention within the past 3 months and/or is likely to result in death within the next 2 years.
  8. Has a history of allergies or hypersensitivity to sitaxsentan or nifedipine or the excipients of either drug.
  9. Has a clinically significant psychiatric, addictive, neurological disease or any other condition that, in the Investigator's opinion, would compromise his/her ability to give informed consent, participate fully in this study, prevent adherence to the requirements of the study protocol, or would compromise the interpretation of the data obtained from this study.
  10. Uses a prohibited medication or plans to use a prohibited medication during the study.

    • Prohibited medications include cyclosporine A, alternative endothelin (ET) receptor antagonists, phosphodiesterase inhibitors, and/or vitamin K antagonists (e.g., warfarin). The intermittent use of phosphodiesterase inhibitors (e.g., sildenafil) "as needed" for erectile dysfunction is acceptable, however, as long as the subject is not dosed within 24 hours of an efficacy assessment.
  11. Received treatment with an investigational drug or device within 30 days prior to study entry.
  12. Has a history of organ transplantation.
  13. Has atrial fibrillation requiring anticoagulation or a history (in the preceding 6 months) of any intermittent cardiac dysrhythmia that may require anticoagulation therapy.
  14. Has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) level > 1.5 × the upper limit of the normal range (ULN) at Screening and/or serum total bilirubin > ULN.
  15. Has a haemoglobin concentration < 8.0 mg/dL at Screening.
  16. Has positive serological results for hepatitis B and/or hepatitis C.
  17. Is a woman of childbearing potential who is unwilling to use 2 forms of contraceptive therapy, including at least 1 barrier method, throughout the study. (Women who are surgically sterile or who are post-menopausal for at least 2 years are not considered to be of childbearing potential.)
  18. Is pregnant, lactating, or breastfeeding.
  19. Has, in the opinion of the Investigator, a dependence on alcohol.
  20. Has, in the opinion of the Investigator, a dependence on illicit drugs.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00817037

Locations
United Kingdom
Clinical Research Centre, Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU
Sponsors and Collaborators
University of Edinburgh
Encysive Pharmaceuticals
Investigators
Study Director: David Webb, MD DSc FRCP FRSE FMedSci University of Edinburgh
Principal Investigator: Neeraj Dhaun, MBChB University of Edinburgh
  More Information

No publications provided

Responsible Party: Professor David Webb MD DSc FRCP FRSE FMedSci, University of Edinburgh
ClinicalTrials.gov Identifier: NCT00817037     History of Changes
Other Study ID Numbers: 2007/W/CRC/02, CTA# 2006-002004-33, 06/MRE10/69
Study First Received: January 5, 2009
Last Updated: January 5, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Edinburgh:
Chronic kidney disease
Proteinuria
Blood pressure
Arterial stiffness
Endothelin antagonist
Sitaxsentan

Additional relevant MeSH terms:
Kidney Diseases
Proteinuria
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Renal Insufficiency
Nifedipine
Tocolytic Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on April 17, 2014